|

Plixorafenib Clinical Trials

1 actively recruiting trial across 1 location

No change since May 2026

Also known as: FORE8394, PLX8394

Pipeline

Phase 2: 1

Top Sponsors

  • Fore Biotherapeutics1

Indications

  • LGG1
  • HGG1
  • Cancer Harboring BRAF Alterations1
  • Solid Tumors1
  • Cancer1

Beverly Hills, California1 trial

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Precision NextGen Oncology & Research Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.